# Scot Ebbinghaus

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/scot-ebbinghaus/

## Facts

| Field | Value |
| --- | --- |
| Citations | 27,668 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 46 |
| i10-index | 93 |
| Last Known Institution | Merck & Co., Inc., Rahway, NJ, USA (United States) |
| OpenAlex ID | https://openalex.org/A5005775401 |
| Works | 177 |

## Researcher papers

- [Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial](https://scholariq.org/papers/pembrolizumab-in-patients-with-advanced-hepatocellular-carcinoma-previously/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)

## Researcher university

- [Merck & Co., Inc., Rahway, NJ, USA (United States)](https://scholariq.org/institutions/merck-and-co-inc-rahway-nj-usa-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.